2 unique CVOTs - CARMELINA® and CAROLINA® - have been designed to establish long-term safety of TRAJENTA in a broad range of T2D patients1,2.

Carmelina Logo

A unique CV outcome trial in T2D, as it also included a key secondary composite kidney endpoint to evaluate the long-term kidney safety of TRAJENTA®1

  • Heart icon
  • Kidney icon
  • Patients with established CV disease and/or CKD
  • N=6,980
  • HbA1c 6.5-10%
Carolina Logo

The only DPP4i CVOT with an active comparator (glimepride)2

  • Heart icon
  • Early T2D patients
  • N=6,072
  • HbA1c 6.5-8.5%

A robust CVOT program establishing TRAJENTA® long-term safety

for a broad range of patients